source
- Beeline Medicines reports promising Phase 2 results for lupus using repurposed Bristol Myers drugBeeline Medicines announced that its Phase 2 trial in systemic lupus erythematosus produced encouraging results. The study tested three different doses of a compound originally discovered by Brist…
- VectorY Therapeutics raises $83.5M Series A to develop brain-targeted antibody gene therapyVectorY Therapeutics announced it has closed a Series A financing round, adding €74.5 million ($83.5 million) to its capital. The funds will be used to advance its lead gene-therapy candidate VTx-…